Microba raises A$5M post-IPO placement to chase cash-flow breakeven
What's the deal? Australian microbiome diagnostics company Microba Life Sciences has raised $5 million through a post-IPO equity placement, targeting company-wide cash flow breakeven. The ASX-listed firm is issuing over 100 million new shares at A$0.05 each.
Sonic HealthcareDealroom has a profile for this one. Try Dealroom →, a major partner, is investing $1.5 million as part of the round. The rest comes from existing and new institutional and sophisticated investors.
Microba is also launching a share purchase plan to raise an additional $1 million, allowing eligible shareholders in Australia and New Zealand to buy up to A$30,000 of new shares at the same price. Participants in both the placement and the plan will receive one unlisted option for every new share, exercisable at A$0.0625 and expiring in three years.
Why now? The company has posted 11 consecutive quarters of core testing sales growth, with revenue up 106% over the past 12 months. That momentum is driven by enterprise-style healthcare contracts — a sign that Microba's microbiome testing is gaining traction with larger institutional buyers, not just individual consumers.
A new "category-defining" testing product is also slated for launch in Q3, giving the company a reason to raise capital now to support both the rollout and its path to profitability.
What could go wrong? The placement price of A$0.05 per share and the scale of dilution — over 100 million new shares — suggest the company is still early-stage in financial terms despite its listing. Microbiome diagnostics remains a nascent market, and reaching breakeven will depend on whether enterprise contracts continue to scale and the new product delivers on its promise.
Sonic Healthcare's backing provides credibility, but at $1.5 million it is a modest commitment from a company with a market cap exceeding A$15 billion.
The signal: Microba's targeted raise to reach breakeven — rather than to fuel aggressive expansion — fits a broader pattern among listed health-tech companies that survived the post-2022 funding squeeze: smaller, purpose-driven rounds aimed at profitability. Sonic Healthcare's participation as a corporate investor, albeit modest at $1.5 million, lends clinical credibility to microbiome diagnostics at a time when the sector is still working to prove itself beyond the wellness market.
Read more: grafa.com
